AMT-060, a first-generation gene therapy candidate by uniQure, continues to safely reduce the number of bleeding episodes and the use of clotting factor IX (FIX) in men with moderate to severe hemophilia B, long-term data from a Phase 1/2 clinical trial show. The therapy also prevented…

CAR T-cell therapy, a type of treatment that weaponizes the body’s immune system and was originally developed to treat cancer, for the first time successfully treated a patient with acquired hemophilia A (AHA), a study reported. The study, “Anti-CD19 CAR-T cell therapy for acquired hemophilia A,”…

Welcome to 2022, a new year and a clean slate. Year after year, my New Year’s resolutions are the same: eat a more healthy diet, work out, and lose weight. This year will be different. Recently, a nurse phoned from the specialty pharmacy that provides medication to treat my von…

My husband, Jared, enjoys cooking. As I write this, a pot of gumbo simmers on the stove. Its strong aroma drifts throughout our open-layout house and toward my work desk. My stomach churns in excitement. It’s his first time making this dish, but as with nearly every recipe…

The internet is overflowing with life hacks that can make tasks easier. From using a plastic knife to cleanly cut brownies to using pillowcases to clean ceiling fan blades, there are hundreds of tricks to help people solve problems. For example, I recently grabbed a roll of Press’n Seal…

Preparing for change is never easy. For Caeleb, my youngest son, this season of his life is stressful yet exciting. After graduating from high school, he is marching on as a freshman at the University of New Mexico this fall. He’s excited about attending college, but has some…

One of my favorite movies is “Galaxy Quest,” a comedy that parodies and pays homage to science fiction films and TV. In it, the cast members of a cult series much like “Star Trek” are drawn into an interstellar conflict by real aliens who think the series is…

Sigilon Therapeutics’s Afibromer SIG-003 candidate for the long-term treatment of patients with hemophilia B recently received an Advanced Therapy Medicinal Product (ATMP) designation in the European Union. The designation was granted by the Committee for Advanced Therapies of…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status (ODD) to Catalyst Biosciences’ highly potent recombinant human factor IX variant CB 2679d (also known as ISU304) to treat hemophilia B. Catalyst is evaluating CB 2679d’s potential for subcutaneous prophylactic treatment in people with hemophilia B. The regulatory decision…

The biotech companies Swedish Orphan Biovitrum AB (Sobi) and Biogen have announced that the European Commission (EC) has approved their extended half-life therapy Alprolix (rFIXFc) for hemophilia B in all 28 European Union (EU) countries. In addition, the EC maintained the drug’s orphan designation. The World Federation of Hemophilia (WFH) estimated…